Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

ArQule, Inc. (Nasdaq: ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from the company's Phase 1 dose escalation study...

ARQL : 3.38 (-1.74%)
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting

ArQule, Inc. (Nasdaq:ARQL) today announced that it will present clinical data on the company's BTK inhibitor, ARQ 531, in a poster presentation at the 60th American Society of Hematology...

ARQL : 3.38 (-1.74%)
ArQule Presents Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium

ArQule, Inc. (Nasdaq: ARQL) today announced the presentation of clinical and preclinical data on ARQ 751 in three poster presentations at the 30th EORTC/AACR/NCI Symposium held from November...

ARQL : 3.38 (-1.74%)
Options Traders Expect Huge Moves in ArQule (ARQL) Stock

ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.

ARQL : 3.38 (-1.74%)
ArQule to Present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Head of Strategy, Finance, and Communication will present...

ARQL : 3.38 (-1.74%)
ArQule to Present Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium

ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting clinical and preclinical data on the company's next generation AKT inhibitor, ARQ 751, in three poster presentations...

ARQL : 3.38 (-1.74%)
ArQule (ARQL) Reports Q3 Loss, Tops Revenue Estimates

ArQule (ARQL) delivered earnings and revenue surprises of 16.67% and 104.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

ARQL : 3.38 (-1.74%)
ArQule Reports Third Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2018.

ARQL : 3.38 (-1.74%)
New Research Coverage Highlights TIER REIT, Meridian Bioscience, ArQule, Greenlight Capital Re, ADT, and Turquoise Hill Resources -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TIER REIT, Inc. (NYSE:TIER),...

ADT : 7.19 (-2.84%)
ARQL : 3.38 (-1.74%)
TRQ : 1.66 (-0.60%)
VIVO : 18.19 (-0.82%)
TIER : 22.12 (+0.68%)
GLRE : 9.45 (-3.87%)
ArQule Presents Orphan Disease Clinical Data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for Its pan-AKT Inhibitor, Miransertib (ARQ 092)

ArQule, Inc. (Nasdaq:ARQL) today announced the presentation of preliminary clinical data on miransertib (ARQ 092) in three poster presentations at the American Society of Human Genetics (ASHG)...

ARQL : 3.38 (-1.74%)
ArQule to Report Third Quarter 2018 Financial Results on October 31, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2018 before the market opens on Wednesday, October 31, 2018. The Company will...

ARQL : 3.38 (-1.74%)
ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics (ASHG) 2018 Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting clinical data on the company's lead AKT inhibitor, miransertib (ARQ 092), in three poster presentations at the American...

ARQL : 3.38 (-1.74%)
ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018

ArQule, Inc. (Nasdaq:ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, and...

ARQL : 3.38 (-1.74%)
ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the...

ARQL : 3.38 (-1.74%)
Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS)

ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to miransertib (ARQ 092) for the treatment of PIK3CA-Related...

ARQL : 3.38 (-1.74%)
Implied Volatility Surging for ArQule (ARQL) Stock Options

Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.

ARQL : 3.38 (-1.74%)
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.

ARQL : 3.38 (-1.74%)
SMMT : 1.22 (-2.40%)
PFE : 44.57 (+0.93%)
MKGAF : 109.6500 (-0.14%)
ArQule Reports First Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2018.

ARQL : 3.38 (-1.74%)
ArQule, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 7, 2018 / ArQule, Inc. (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 7, 2018 at 9:00 AM Eastern Time.

ARQL : 3.38 (-1.74%)
ArQule to Report First Quarter 2018 Financial Results on May 7, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter of 2018 before the market opens on Monday, May 7, 2018. The Company will hold a conference...

ARQL : 3.38 (-1.74%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA +10.19
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures ended the Thursday session with most contracts steady to a penny lower. Dec futures expire on Friday. This morning’s USDA Export Sales report showed 18/19 corn sales in the week of 12/6 at 903,164 MT, shy of trade estimates. That w...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar